VTE prophylaxis ‘needed,’ significantly reduces death in high-risk patients with cancer

Guideline-concordant thromboprophylaxis significantly reduces both venous thromboembolism and death in patients at high risk for blood clots. Data from a multidisciplinary VTE prevention program instituted at University of Vermont showed high-risk patients beginning systemic cancer therapy who received thromboprophylaxis had a 64% lower likelihood of VTE and 54% lower likelihood of death.